Summit Therapeutics (SMMT) Is Up 6.5% After FDA Accepts Ivonescimab BLA With 2026 PDUFA Date

• Summit Therapeutics Inc. previously announced that the FDA accepted for filing its Biologics License Application for ivonescimab plus chemotherapy in EGFR‑mutated, locally advanced or metastatic non-squamous NSCLC after tyrosine kinase inhibitor therapy, assigning a PDUFA action date of November 14, 2026.
• Beyond this U.S. filing, Summit and partner Akeso have broadened ivonescimab’s late-stage program across multiple Phase III trials and tumor types, underscoring a concerted push to position the antibody in several major oncology indications.
• With the FDA’s BLA acceptance and PDUFA date set for ivonescimab in post-TKI NSCLC, we’ll explore how this milestone shapes Summit’s investment narrative.

The future of work is here. Discover the 29 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

What Is Summit Therapeutics' Investment Narrative?

For Summit Therapeutics, being a shareholder really comes down to believing that ivonescimab can transition from an early-stage story to a commercially relevant oncology platform. The FDA’s acceptance of the BLA in post‑TKI EGFR‑mutated NSCLC, with a defined PDUFA date in late 2026, gives the company a clearer regulatory path and adds structure to the near‑term catalyst calendar, even if it does not immediately change the underlying risks of a zero‑revenue, loss‑making business. The bigger shift is that the filing, combined with an expanded Phase III footprint and new collaborations with GSK and Pfizer, ties Summit’s fortunes even more tightly to ivonescimab’s clinical and regulatory execution. That concentration heightens binary risk around trial outcomes, capital needs and dilution, particularly with the share price still volatile after recent weakness.

However, there is one concentration risk here that investors should not overlook. Summit Therapeutics' shares have been on the rise but are still potentially undervalued. Find out how large the opportunity might be.

Exploring Other Perspectives

Six fair value estimates from the Simply Wall St Community span roughly US$22 to over US$220 per share, underlining how far apart views are. When you set that wide dispersion against Summit’s single‑product focus and upcoming regulatory milestones, it becomes clear why opinion is so split and why reviewing several perspectives can be useful before forming your own stance.

Explore 6 other fair value estimates on Summit Therapeutics - why the stock might be a potential multi-bagger!

Build Your Own Summit Therapeutics Narrative

Disagree with this assessment? Create your own narrative in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Summit Therapeutics research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Summit Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Summit Therapeutics' overall financial health at a glance.

Searching For A Fresh Perspective?

Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:

• This technology could replace computers: discover 23 stocks that are working to make quantum computing a reality.
• Capitalize on the AI infrastructure supercycle with our selection of the 33 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• AI is about to change healthcare. These 26 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com